Related Experiment Videos
Interfering with TGFbeta-induced Smad3 nuclear accumulation differentially affects TGFbeta-dependent gene expression.
Ralph K Lindemann1, Alfred Nordheim, Jürgen Dittmer
1Institut für Zellbiologie, Abteilung Molekularbiologie, Universität Tübingen, Auf der Morgenstelle 15, 72076 Tübingen, Germany. ralph.lindemann@uni-tuebingen.de
Molecular Cancer
|May 16, 2003
Summary
Two TGFbeta inhibitors, SB-202190 and SB-203580, were found to suppress key genes driving cancer invasion and metastasis. These compounds show potential for inhibiting malignant cell behavior by interfering with TGFbeta signaling pathways.
Area of Science:
- Oncology
- Molecular Biology
- Cell Biology
Background:
- Transforming growth factor-beta (TGFbeta) is crucial in late-stage carcinogenesis, promoting cancer cell invasion, angiogenesis, and immune evasion.
- TGFbeta also facilitates bone metastasis by increasing parathyroid hormone-related protein (PTHrP) expression in breast cancer cells.
- Targeting TGFbeta signaling offers a potential strategy to reduce cancer cell malignancy.
Purpose of the Study:
- To investigate the efficacy of SB-202190 and SB-203580 as inhibitors of TGFbeta signaling in invasive MDA-MB-231 breast cancer cells.
- To determine the impact of these inhibitors on TGFbeta-induced gene expression related to cancer progression.
Main Methods:
- Utilized invasive MDA-MB-231 breast cancer cells.
- Administered SB-202190 and SB-203580, known inhibitors of TGFbeta type I receptor kinase.
- Assessed TGFbeta-induced nuclear accumulation of Smad3.
- Quantified the expression of TGFbeta-responsive genes, including pthrp, pai-1, upa, smad7, and ese-1/esx.
Main Results:
- SB-202190 and SB-203580 delayed Smad3 nuclear accumulation and reduced its amplitude in response to TGFbeta.
- The inhibitors significantly reduced the expression of slow-responder genes (pthrp, pai-1, upa) crucial for invasion.
- Expression of the fast-responder gene smad7 and ese-1/esx remained largely unaffected by the inhibitors.
Conclusions:
- SB-202190 and SB-203580 effectively suppress TGFbeta-dependent gene activation linked to invasive cancer cell behavior.
- These compounds do not interfere with the expression of the natural TGFbeta inhibitor, Smad7.
- The findings suggest SB-202190 and SB-203580 are potent inhibitors of cancer cell malignancy.